.
BioEnterprise

BioMotiv Spins Off New Company that Aims to Thwart Cell Deaths

BioMotiv, a Cleveland drug development accelerator associated with The Harrington Project, the University of California San Francisco (UCSF), and University of Washington, Seattle, has launched OptiKira. The new company will develop therapies to treat retinitis pigmentosa, diabetes, and ALS.

Read More  >